The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in Korean

A multicenter prospective study

Du Geon Moon, Min Gu Park, Sung Won Lee, Kwangsung Park, Jong Kwan Park, Sae Woong Kim, Nam Cheol Park, Tai Young Ahn, Jae Seung Paick, Ju Tae Seo, Dae Yul Yang, Juneyoung Lee, Je-Jong Kim

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction.: Long-acting injectable testosterone undecanoate (TU, Nebido®), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. Aims.: To assess the efficacy and safety of long-acting injectable testosterone undecanoate (TU, Nebido®) in Korean patients with testosterone deficiency syndrome (TDS). Methods.: One hundred thirty-three patients who complain of erectile dysfunction with serum testosterone level less than 3.5 ng/mL were injected with 1,000 mg of TU (4 mL/ample) on day 1, followed by another injection after 6 weeks and 18 weeks. For the safety profiles, serum hemoglobin (Hb), hematocrit (Hct), glucose, lipid profile, and prostate-specific antigen (PSA) were measured. Main Outcome Measures.: Body mass index (BMI) was measured at the time of the first visit and after 12, 24 weeks. Primary efficacy was evaluated according to changes in the International Index of Erectile Function (IIEF) from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Secondary efficacy was assessed with changes of the Aging Males' Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function. Results.: Mean age of patients was 54 ± 9.6 years. Compared with pretreatment, no significant improvement in BMI was observed. Serum total testosterone and free testosterone were significantly increased at 12 weeks and were maintained until 24 weeks (P < 0.001). TU significantly decreased cholesterol (P < 0.0001). TU significantly improved total IIEF, all five domain scores of IIEF (P < 0.0001) and total AMS, all three domain scores of AMS (P < 0.0001). On GEQ, TU improved erectile function in 76.9% of subjects. On safety profile, TU significantly elevated Hb, Hct, and PSA at 24 weeks but within normal range. No serious adverse reactions were observed. Drop-out rate was 15.0%. Conclusions.: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow.

Original languageEnglish
Pages (from-to)2253-2260
Number of pages8
JournalJournal of Sexual Medicine
Volume7
Issue number6
DOIs
Publication statusPublished - 2010 Jan 1

Fingerprint

Multicenter Studies
Testosterone
Prospective Studies
Safety
Injections
Prostate-Specific Antigen
Hematocrit
Hemoglobins
Body Mass Index
Serum
Erectile Dysfunction
testosterone undecanoate
Esters
Reference Values
Cholesterol
Outcome Assessment (Health Care)
Lipids
Glucose

Keywords

  • Hypogonadism
  • Korea
  • Testosterone Deficiency Syndrome
  • Testosterone Undecanoate

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Urology

Cite this

The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in Korean : A multicenter prospective study. / Moon, Du Geon; Park, Min Gu; Lee, Sung Won; Park, Kwangsung; Park, Jong Kwan; Kim, Sae Woong; Park, Nam Cheol; Ahn, Tai Young; Paick, Jae Seung; Seo, Ju Tae; Yang, Dae Yul; Lee, Juneyoung; Kim, Je-Jong.

In: Journal of Sexual Medicine, Vol. 7, No. 6, 01.01.2010, p. 2253-2260.

Research output: Contribution to journalArticle

Moon, Du Geon ; Park, Min Gu ; Lee, Sung Won ; Park, Kwangsung ; Park, Jong Kwan ; Kim, Sae Woong ; Park, Nam Cheol ; Ahn, Tai Young ; Paick, Jae Seung ; Seo, Ju Tae ; Yang, Dae Yul ; Lee, Juneyoung ; Kim, Je-Jong. / The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in Korean : A multicenter prospective study. In: Journal of Sexual Medicine. 2010 ; Vol. 7, No. 6. pp. 2253-2260.
@article{e733189d316c401698cd482e9a26fecc,
title = "The efficacy and safety of testosterone undecanoate (nebido{\circledR}) in testosterone deficiency syndrome in Korean: A multicenter prospective study",
abstract = "Introduction.: Long-acting injectable testosterone undecanoate (TU, Nebido{\circledR}), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. Aims.: To assess the efficacy and safety of long-acting injectable testosterone undecanoate (TU, Nebido{\circledR}) in Korean patients with testosterone deficiency syndrome (TDS). Methods.: One hundred thirty-three patients who complain of erectile dysfunction with serum testosterone level less than 3.5 ng/mL were injected with 1,000 mg of TU (4 mL/ample) on day 1, followed by another injection after 6 weeks and 18 weeks. For the safety profiles, serum hemoglobin (Hb), hematocrit (Hct), glucose, lipid profile, and prostate-specific antigen (PSA) were measured. Main Outcome Measures.: Body mass index (BMI) was measured at the time of the first visit and after 12, 24 weeks. Primary efficacy was evaluated according to changes in the International Index of Erectile Function (IIEF) from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Secondary efficacy was assessed with changes of the Aging Males' Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function. Results.: Mean age of patients was 54 ± 9.6 years. Compared with pretreatment, no significant improvement in BMI was observed. Serum total testosterone and free testosterone were significantly increased at 12 weeks and were maintained until 24 weeks (P < 0.001). TU significantly decreased cholesterol (P < 0.0001). TU significantly improved total IIEF, all five domain scores of IIEF (P < 0.0001) and total AMS, all three domain scores of AMS (P < 0.0001). On GEQ, TU improved erectile function in 76.9{\%} of subjects. On safety profile, TU significantly elevated Hb, Hct, and PSA at 24 weeks but within normal range. No serious adverse reactions were observed. Drop-out rate was 15.0{\%}. Conclusions.: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow.",
keywords = "Hypogonadism, Korea, Testosterone Deficiency Syndrome, Testosterone Undecanoate",
author = "Moon, {Du Geon} and Park, {Min Gu} and Lee, {Sung Won} and Kwangsung Park and Park, {Jong Kwan} and Kim, {Sae Woong} and Park, {Nam Cheol} and Ahn, {Tai Young} and Paick, {Jae Seung} and Seo, {Ju Tae} and Yang, {Dae Yul} and Juneyoung Lee and Je-Jong Kim",
year = "2010",
month = "1",
day = "1",
doi = "10.1111/j.1743-6109.2010.01765.x",
language = "English",
volume = "7",
pages = "2253--2260",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - The efficacy and safety of testosterone undecanoate (nebido®) in testosterone deficiency syndrome in Korean

T2 - A multicenter prospective study

AU - Moon, Du Geon

AU - Park, Min Gu

AU - Lee, Sung Won

AU - Park, Kwangsung

AU - Park, Jong Kwan

AU - Kim, Sae Woong

AU - Park, Nam Cheol

AU - Ahn, Tai Young

AU - Paick, Jae Seung

AU - Seo, Ju Tae

AU - Yang, Dae Yul

AU - Lee, Juneyoung

AU - Kim, Je-Jong

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Introduction.: Long-acting injectable testosterone undecanoate (TU, Nebido®), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. Aims.: To assess the efficacy and safety of long-acting injectable testosterone undecanoate (TU, Nebido®) in Korean patients with testosterone deficiency syndrome (TDS). Methods.: One hundred thirty-three patients who complain of erectile dysfunction with serum testosterone level less than 3.5 ng/mL were injected with 1,000 mg of TU (4 mL/ample) on day 1, followed by another injection after 6 weeks and 18 weeks. For the safety profiles, serum hemoglobin (Hb), hematocrit (Hct), glucose, lipid profile, and prostate-specific antigen (PSA) were measured. Main Outcome Measures.: Body mass index (BMI) was measured at the time of the first visit and after 12, 24 weeks. Primary efficacy was evaluated according to changes in the International Index of Erectile Function (IIEF) from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Secondary efficacy was assessed with changes of the Aging Males' Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function. Results.: Mean age of patients was 54 ± 9.6 years. Compared with pretreatment, no significant improvement in BMI was observed. Serum total testosterone and free testosterone were significantly increased at 12 weeks and were maintained until 24 weeks (P < 0.001). TU significantly decreased cholesterol (P < 0.0001). TU significantly improved total IIEF, all five domain scores of IIEF (P < 0.0001) and total AMS, all three domain scores of AMS (P < 0.0001). On GEQ, TU improved erectile function in 76.9% of subjects. On safety profile, TU significantly elevated Hb, Hct, and PSA at 24 weeks but within normal range. No serious adverse reactions were observed. Drop-out rate was 15.0%. Conclusions.: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow.

AB - Introduction.: Long-acting injectable testosterone undecanoate (TU, Nebido®), a new parenteral testosterone preparation, has recently been introduced to avoid frequent injections of the conventional injectable esters. Aims.: To assess the efficacy and safety of long-acting injectable testosterone undecanoate (TU, Nebido®) in Korean patients with testosterone deficiency syndrome (TDS). Methods.: One hundred thirty-three patients who complain of erectile dysfunction with serum testosterone level less than 3.5 ng/mL were injected with 1,000 mg of TU (4 mL/ample) on day 1, followed by another injection after 6 weeks and 18 weeks. For the safety profiles, serum hemoglobin (Hb), hematocrit (Hct), glucose, lipid profile, and prostate-specific antigen (PSA) were measured. Main Outcome Measures.: Body mass index (BMI) was measured at the time of the first visit and after 12, 24 weeks. Primary efficacy was evaluated according to changes in the International Index of Erectile Function (IIEF) from the initial visit to the final visit (24 weeks) and from the initial visit to each visit. Secondary efficacy was assessed with changes of the Aging Males' Symptoms (AMS) Scale and the Global Efficacy Question (GEQ) for improvement of erectile function. Results.: Mean age of patients was 54 ± 9.6 years. Compared with pretreatment, no significant improvement in BMI was observed. Serum total testosterone and free testosterone were significantly increased at 12 weeks and were maintained until 24 weeks (P < 0.001). TU significantly decreased cholesterol (P < 0.0001). TU significantly improved total IIEF, all five domain scores of IIEF (P < 0.0001) and total AMS, all three domain scores of AMS (P < 0.0001). On GEQ, TU improved erectile function in 76.9% of subjects. On safety profile, TU significantly elevated Hb, Hct, and PSA at 24 weeks but within normal range. No serious adverse reactions were observed. Drop-out rate was 15.0%. Conclusions.: In this prospective multicenter study, TU was effective, safe, and tolerable until 24 weeks in Korean TDS patients. Further well-controlled, long-term study should follow.

KW - Hypogonadism

KW - Korea

KW - Testosterone Deficiency Syndrome

KW - Testosterone Undecanoate

UR - http://www.scopus.com/inward/record.url?scp=77953918921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953918921&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2010.01765.x

DO - 10.1111/j.1743-6109.2010.01765.x

M3 - Article

VL - 7

SP - 2253

EP - 2260

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 6

ER -